Gravity Analytica

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SRPT 01.06.2025

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-13

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our SRPT Tweets

About Gravity Analytica

Recent Filings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2025--Sarepta Therapeutics, Inc.(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 43rd AnnualJ.P. Morgan Healthcare ConferenceinSan Francisco, Calif.onMonday, Jan. 13, 2025at12:00 p.m. E.T./9:00 a.m. P.T.Following the presentation there will be a Q&A session starting at12:20 p.m. E.T./9:20 a.m. P.T.

The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website athttps://investorrelations.sarepta.com/events-presentationsand will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

AboutSarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visitwww.sarepta.comor follow us onLinkedIn,X,InstagramandFacebook.

Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250106832295/en/

Investor Contact:Ian Estepan, 617-274-4052iestepan@sarepta.com

Media Contact:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com

Source:Sarepta Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com